Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-999-9 | CAS number: 280-57-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 1,4-diazabicyclooctane
- EC Number:
- 205-999-9
- EC Name:
- 1,4-diazabicyclooctane
- Cas Number:
- 280-57-9
- Molecular formula:
- C6H12N2
- IUPAC Name:
- 1,4-diazabicyclooctane
- Details on test material:
- - Name of test material (as cited in study report): 1,4 - diazabicyclooctane- Common name: TEDA
Constituent 1
- Specific details on test material used for the study:
- Test item: TEDA (1,4-Diazabicyclo[2.2.2]octane
Supplier: Chemical Marketing Concepts
200 Pickett District Road
New Milford, Connecticut 06766
Description: White crystalline solid
Storage conditions: Cool (8 to 15°C from receipt to GD 8 Set 1; GD 6 Set 2; 8 to
25°C thereafter)
Lot number: 2090462
Purity: 99.97%
Expiration date: 10 January 2018
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Details on test animals or test system and environmental conditions:
- Animal model Albino Rats (Outbred) VAF/Plus
CD (Sprague-Dawley derived) [Crl:CD (SD)BR]
Supplier Charles River Laboratories
Raleigh, North Carolina 27610
Number of animals
received/placed on test
80 time-mated females
The female rats selected for breeding were nulliparous and
previously virgin and not mated with male siblings.
Age of the animals at
receipt
Approximately 10 to 12 weeks on GD 0, where GD 0 was the
day of detection of a copulatory plug in situ and/or sperm in a
vaginal smear.
Currently acceptable practices of good animal husbandry were followed
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Will be provided when final study report is available
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis of preliminary mixes confirmed that the preparation procedure used for this study
produced homogeneous mixtures. Analyses conducted during the exposure period confirmed
that dose formulations of appropriate concentration were administered. - Duration of treatment / exposure:
- From GD 6 to 19, inclusive, where GD 0 is the day of detection of mating (copulatory plug in situ and/or sperm in a vaginal smear).
- Frequency of treatment:
- The test and control (vehicle) items were administered once daily, 7 days per week, from GD 6 to 19, inclusive, where GD 0
is the day of detection of mating (copulatory plug in situ and/or sperm in a vaginal smear). - Duration of test:
- All surviving animals were euthanized on GD 20
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 20 femaled per group
- Control animals:
- yes
Examinations
- Maternal examinations:
- - clinical signs
- body weight
- food consumtions
- clinical chemistry
- macroscopic examination
- organ weights
- histopathology
Clinical chemistry
Aspartate aminotransferase (AST) (Kinetic - Modified Bergmeyer)
Alanine aminotransferase (ALT) (Kinetic - Modified Bergmeyer)
Alkaline phosphatase (ALKP) (Kinetic – Tietz AMP Buffer)
Blood urea nitrogen (BUN) (Enzymatic – Roch-Ramek with Urease)
Creatinine (CREAT) (Jaffe Picric Acid in Alkaline Medium)
Glucose (GLU) (Glucose Hexokinase II Method)
Cholesterol (CHOL) (Enzymatic esterase/oxidase – Trinder Endpoint)
Triglycerides (TRIG) (Fossati Three Step Enzymatic – Trinder Endpoint)
Total protein (TP) (Biuret Technique)
Albumin (ALB) (Bromocresol Green Method)
Total bilirubin (TBILI) (Oxidation with Vandate)
Sodium (NA+) (Ion Selective Electrode)
Potassium (K+) (Ion Selective Electrode)
Chloride (Cl-) (Ion Selective Electrode)
Calcium (Ca++) (Michaylova & Ilkova, Arsenazo III)
Inorganic phosphorus (PHOS) (Phosphomolybdate – UV Method) - Fetal examinations:
- - External Examinations
- Soft Tissue (Visceral) Examinations
- Skeletal Examinations - Statistics:
- Unrounded individual animal data were used to calculate the reported mean and standard deviation values. Therefore, use of the reported individual values to reproduce means, standard deviations and/or to perform any subsequent calculations may produce minor discrepancies between the calculated values and those presented in this report. Group means and standard deviations for calculated data points (i.e. body weight change) were derived from individual animal values.
The following data types were analyzed at each timepoint separately:
maternal body weight
maternal interval body weight change
food consumption
fetal weights per litter
placental weights per litter
litter size
count of corpora lutea
count of implantation sites
percent pre-implantation loss
percent post-implantation loss (resorptions and early/fetal deaths)
sex ratio per litter
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no test item-related clinical observations during the study.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- Two unscheduled deaths occurred in the 1000 mg/kg/day group. The cause of death and relationship of mortality to the test item could not be determined in either animal. Animal
No. 4564 was found dead on GD 13 and had no ante mortem clinical findings or macroscopic abnormalities at necropsy. Animal No. 4565 was found dead on GD 18. It exhibited moist rales
on GD’s 10 and 11 and had a moderately enlarged liver at necropsy which was not examined microscopically. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The 100 and 300 mg/kg/day groups had gestation body weight and body weight gain values which were comparable to control values.
There were test item-related effects on gestation body weights and body weight gains at 1000 mg/kg/day. Statistically significant, test item-related decreases in absolute body weights and body weight loss/decreased body weight gain were noted in females at 1000 mg/kg/day throughout the dosing and one-day recovery periods. Despite the slight decreased absolute body weight pretest (GD 3 and 6), decreases in absolute body weight ranged from -10% to -14% as compared with mean control values, with the greatest decrease (loss) from GDs 6 to 9. Weights increased slightly
thereafter, but body weight gains were still reduced by 34% when compared with mean control values for the entire study (GDs 6 to 20). - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The 100 and 300 mg/kg/day groups had food consumption values which were comparable to control values.
Statistically significant, test item-related decreases in food consumption were observed in females at 1000 mg/kg/day, occurring throughout the dosing and one-day recovery periods. The greatest decreases occurred from GDs 6 to 9 (-55% as compared to mean control values) and increased slightly thereafter, but were still reduced by 32% when compared with mean control values for the entire study (GDs 6 to 20). - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The 100 and 300 mg/kg/day exposure groups had clinical chemistry values which were comparable to control values.
Test item-related clinical chemistry changes at 1000 mg/kg/day included increases in alkaline phosphatase activity (1.33× control) and decreases in total protein (0.87× control), albumin
(0.86× control), and globulins (0.88× control). These changes are considered non-adverse due to their relatively small magnitude and are likely due to decreases in food consumption identified at
1000 mg/kg/day. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no test item-related organ weight changes in the liver or kidneys. The absolute weights of the liver and kidneys were reduced in the 1000 mg/kg/day group, however the relative organ weights (as a percentage of body weight) of the liver and kidneys were comparable with the control group values. These changes are considered non-adverse due to their relatively small magnitude and are likely due to decreases in body weight and food consumption identified at 1000 mg/kg/day.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Macroscopic
There were no test item-related macroscopic findings.
All macroscopic findings occurred sporadically or at similar incidence and severity in the control and test item-treated groups and were considered incidental and due to biological variability.
Microscopic
TEDA-related microscopic findings were present in the kidneys at 1000 mg/kg/day and urinary bladder at ≥300 mg/kg/day.
Kidneys
Minimal to slight acute/subacute inflammation was present within the renal pelvis or medullary interstitium of the kidneys in 2 of 18 (terminal necropsy) animals at 1000 mg/kg/day. Both
animals had minimal to slight urothelial hyperplasia and acute hemorrhage (minimal to slight) within the renal pelvis.
Urinary Bladder
Minimal to slight urothelial hyperplasia was present within the urinary bladder of 1 animal each at a 300 and 1000 mg/kg/day and exhibited a dose related increase in severity. Hyperplasia in
the 300 mg/kg/day animal was associated with slight acute/subacute mucosal inflammation. Urothelial hyperplasia in the 1000 mg/kg/day animal was not associated with inflammation
within the urinary bladder, but occurred in an animal (Animal No. 4578) with inflammation and urothelial hyperplasia in the renal pelvis. Inflammatory and/or proliferative lesions in the
kidneys and/or urinary bladder have been described rats given TEDA at 1000 mg/kg/day and the findings were considered to be test item-related (Air Products and Chemicals Inc., 2013).
All other microscopic findings occurred sporadically or at a similar incidence and severity in control and test item-treated groups and were considered incidental and due to biological
variability. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed - Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- There were no test item-related effects on pregnancy or cesarean section parameters. There were 19, 20, 20 and 20 pregnant females in the 0, 100, 300 and 1000 mg/kg/day groups, respectively.
Control group female Animal No. 1516 was not pregnant. All pregnant females had viable fetuses. Cesarean section parameters (number of corpora lutea, implantations, resorptions, dead fetuses, live fetuses, sex ratio, percent pre-implantation loss and percent postimplantation loss) were comparable to mean control values.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- changes in number of pregnant
- changes in pregnancy duration
- dead fetuses
- early or late resorptions
- effects on pregnancy duration
- maternal abnormalities
- necropsy findings
- number of abortions
- pre and post implantation loss
- total litter losses by resorption
- Dose descriptor:
- NOAEL
- Effect level:
- > 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- gross pathology
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- There were no test item effects on gravid uterine, placental or fetal weights. Adjusted body weights on GD 20 and the adjusted body weight changes on GD 6 to 20 were
reduced in the 1000 mg/kg/day females; however the gravid uterine weight in this group was comparable with the control group values and therefore this effect was considered related to the
decreased body weight gain during the study.
Any changes in placental or fetal weights were small in magnitude, not statistically significant, and/or were generally within the concurrent control range.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Description (incidence and severity):
- There were no test item-related external findings.
Any findings, including all variations and malformations (i.e. cleft palate), were not present in a dose-related manner, were low in incidence, and are common in this strain of laboratory animal
and/or were generally within current published HCD. - Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- There were no test item-related skeletal findings.
Any findings, including all variations and malformations (i.e. misshapen/fused cervical vertebral arches, partially-fused exoccipital, lumbar vertebral centrum fused to arch, fused ribs, and
cleft/split sternebra) were not considered to be test item-related as they occurred in low incidence per litter and group, were not present in a dose-related manner or were present in the control
group, common in this strain of laboratory animal and/or were generally within current published HCD. - Visceral malformations:
- no effects observed
- Description (incidence and severity):
- There were no test item-related visceral findings.
Any findings, including all variations and malformations (i.e. absent bladder, cleft palate, heart malrotated, membranous intraventricular septal defect, lungs thickened/unexpanded, aortic arch
interrupted, and right-sided aortic arch) were not considered to be test item-related as they occurred in low incidence per litter and group, were not present in a dose-related manner or were
present in the control group, common in this strain of laboratory animal and/or were generally within current published HCD. - Other effects:
- not examined
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- external malformations
- skeletal malformations
- visceral malformations
Overall developmental toxicity
- Developmental effects observed:
- no
- Treatment related:
- no
Applicant's summary and conclusion
- Conclusions:
- Prenatal Developmental Toxicity Study via Oral Gavage in Rats was performed with 1,4-diazabicyclooctane. Based on results, the maternal systemic No Observed Adverse Effect Level (NOAEL) was considered to be 100 mg/kg/day due to the microscopic findings of inflammation and hyperplasia in the kidney and/or urinary bladder at ≥300 mg/kg/day, and body weight loss and decreased food consumption at 1000 mg/kg/day. The maternal reproductive and embryo-fetal NOAELs were both determined to be 1000 mg/kg/day (the highest dose administered).
- Executive summary:
Prenatal Developmental Toxicity Study via Oral Gavage in Rats was performed with 1,4-diazabicyclooctane. Dose levels used were 100, 300 and 1 000
mg/kg/day.
Administration of TEDA at 300 mg/kg/day was associated with minimal to slight acute/subacute inflammation and urothelial hyperplasia in the kidneys and/or urinary bladder. Inflammation and hyperplasia were considered to be adverse because they could potentially compromise organ function or the ability to respond to additional environmental challenge.
Statistically significant, test item-related decreases in absolute body weights, body weight loss/decreased body weight gain, and decreased food consumption were noted in females at 1000 mg/kg/day throughout the dosing and one-day recovery periods. Decreases in food consumption likely contributed to the test item-related, non-adverse increases in alkaline phosphatase and decreases in total protein, albumin, and globulins at 1000 mg/kg/day.
Based on these data, the maternal systemic No Observed Adverse Effect Level (NOAEL) was considered to be 100 mg/kg/day due to the microscopic findings of inflammation and hyperplasia in the kidney and/or urinary bladder at 300 mg/kg/day, and body weight loss and decreased food consumption at 1000 mg/kg/day. The maternal reproductive and embryo-fetal NOAELs were both determined to be 1000 mg/kg/day (the highest dose administered).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.